Summary
Twenty patients with advanced malignant melanoma refractory to conventional chemotherapy, were entered into a Phase II study of epirubicin, one of the new doxorubicin analogues. The drug was given at a dose of 90 mg/m2 IV every 3 weeks. One partial response and three disease stabilizations were observed. Nausea and vomiting and alopecia were common. Mild to moderate leukopenia occurred in 6 patients. Three cases of reversible ST-T changes were recorded. The observed response rate of 5% with a 39.2% probability of a true response rate ≥ 10%, does not suggest that epirubicin, in the dose and schedule chosen, is active in metastatic malignant melanoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arcamone F, Penco S, Vigevani A, Redaelli S, Franchi G, Di Marco A, Casazza AM, Dasdia T, Formelli F, Necco A, Soranzo C: Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone. J Med Chem 18:703–707, 1975
Casazza AM, Di Marco A, Bertazzoli C, Formelli F, Giuliani F, Pratesi G: Antitumor activity, toxicity, and pharmacological properties of 4′-epiadriamycin. Proceedings of the 10th International Congress of Chemotherapy, Zurich, Switzerland, Sept 1977, vol II, pp 1257–1260
Ganzina F: 4′-Epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev 10:1–22, 1983
Bonfante V, Bonadonna G, Villani F, Di Fronzo G, Martini A, Casazza AM: Preliminary phase I study of 4′-epi-adriamycin. Cancer Treat Rep 63:915–918, 1979
Schauer PK, Wittes RE, Gralla RJ, Casper ES, Young CW: A phase I trial of 4′-epi-adriamycin. Cancer Clin Trials 4:433–437, 1981
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981
Bonfante V, Villani F Bonadonna G: Toxic and therapeutic activity of 4′-epi-Doxorubicin. Tumori 68:105–111, 1982
Bellet RE, Mastrangelo MJ, Berd D, Lustbader E: Chemotherapy of metastatic malignant melanoma. In Clark WH, Goldman LI, Mastrangelo MJ (ed): Human Malignant Melanoma. Grune & Stratton, New York, 1979, pp 325–351
Hurteloup P, Cappellaere P, Armand JP, Mathè G: Phase II clinical evaluation of 4′-epi-doxorubicin. Cancer Treat Rep 67:337–341, 1983
Young CW, Wittes RE, Jain K, Casper ES: Clinical evaluation of 4-epi-doxorubicin. Proceedings of the 13th International Congress of Chemotherapy, Vienna, Austria, Aug–Sept 1983, Part 215, pp 13–16
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lopez, M., Perno, CF., Papaldo, P. et al. Phase II study of epirubicin in advanced malignant melanoma. Invest New Drugs 2, 315–317 (1984). https://doi.org/10.1007/BF00175383
Issue Date:
DOI: https://doi.org/10.1007/BF00175383